NCT01444300View on ClinicalTrials.gov

Dalfampridine for Imbalance in Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Multiple SclerosisFatigue

Interventions

DRUG

Dalfampridine

10mg, bid, pill taken by mouth for 12 weeks

DRUG

Placebo

placebo pill, bid for 12 weeks

Trial Locations (1)

97239

Oregon Health and Science University, Portland

Sponsors

Collaborators (1)

Acorda Therapeutics

All Listed Sponsors

collaborator

Acorda Therapeutics

INDUSTRY

lead

Oregon Health and Science University

OTHER